A3P

Log in

Ipsen treatment gets a new indication in the US

Dysport, a drug of the French pharmaceutical group Ipsen against spasticity, now enjoys a new marketing authorization in the United States to treat the lower limbs in adults, the group said Friday.

Spasticity is a motor disorder equivalent to an involuntary increase in muscle tone, resulting in persistent stiffness of the muscles, spasms or contractures.

In the United States, Dysport already had several indications: cervical dystonia (spasmodic torticollis) since 2009, spasticity of the upper limbs in adults since 2015 and that of the lower limbs for children two years and older since 2016.

In its aesthetic applications as anti-wrinkle, Dysport, competitor of Allergan Botox, is distributed by the Swiss group of dermatology Galderma.

a3p-100pxhaut logo

 fren

Commit to share
Transmit and progress together
Promoting innovation

The A3P Association is a major player in the pharmaceutical and biotechnology industry.
Created in 1986, it contributes to the good development of the production of medicines and clean and sterile equipment, it runs a network of professionals 21 000, manufacturers and suppliers, as part of International Congress and technical days.

It now has over 1700 members who share their technical experience, scientific and regulatory.

More info on video (Versiongb here )


  group    administrators A3P
    
& Project Managers

letter   newsletter A3P